Zonisamide - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Antiepileptic agents

Included in the formulation

Zonegran®

capsules inwards

Eysay Europe Limited United Kingdom

АТХ:

N.03.A.X.15 Zonisamide

Pharmacodynamics:

Selectively affects the foci of pathological excitation in the cerebral cortex. It blocks potential-sensitive sodium and calcium channels, desynchronizes neuronal excitation, preventing the spread of epileptic activity. Has a weak blocking effect against carbonic anhydrase, enhances the inhibitory effect of gamma-aminobutyric acid.

Pharmacokinetics:After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 2-5 hours. The connection with plasma proteins is 50%.

The therapeutic effect develops after the onset of admission. Metabolism in the liver involving cytochrome CYP3A4 to inactive metabolites.

The half-life is 60 hours. Elimination by the kidneys.

Indications:

It is used to treat epilepsy: first detected, with partial attacks with secondary generalization or without it.

ICD-10

VI.G40-G47.G40 Epilepsy

Contraindications:

Individual intolerance, children under 6 years.

Carefully:

Renal and hepatic insufficiency, urolithiasis (including in the anamnesis), hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Children from 6 years and teenagers

Inside, once a day, depending on the body weight:

20-28 kg: 25-50 mg per day;

29-41 kg: 50-75 mg per day;

42 and more: 100 mg per day.

Adults

Inside, 100 mg per day once, regardless of food intake for 1-2 weeks; 200 mg per day - 3-4 weeks; 300 mg per day - 5-6 weeks. If necessary, the dose rises for 100 mg with a two-week interval to a maximum of 500 mg per day.

The highest daily dose: 500 mg.

The highest single dose: 500 mg.

Side effects:

Central and peripheral nervous system: heat stroke, irritability, agitation, confusion, depression, suicidal thoughts and attempts, hallucinations, ataxia, drowsiness, bradyphrenia, nystagmus, tremor, speech disorders, convulsions.

Respiratory system: shortness of breath, aspiration pneumonia.

Hemopoietic system: agranulocytosis, leukocytosis, aplastic anemia, pancytopenia.

Digestive system: dyspepsia, nausea, constipation or diarrhea, vomiting, pancreatitis, weight loss.

Musculoskeletal system: myasthenia gravis, rhabdomyolysis.

Dermatological reactions: alopecia, anhidrosis, toxic epidermal necrolysis, Stevens-Johnson syndrome.

Sense organs: diplopia.

Urinary system: nephrolithiasis, urolithiasis, hydronephrosis, renal insufficiency.

Allergic reactions.

Overdose:

Increased side effects.

Treatment is symptomatic.

Interaction:

Combines with all antiepileptic drugs.

Special instructions:

Persons caring for patients receiving zonisamide, should be warned about the possibility of patients appearing suicidal thoughts and attempts.

Instructions

Zonisamide (Zonisamidum)